- Home
- AKYA vs CHRS Comparison
AKYA vs CHRS Comparison
Compare AKYA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- CHRS
- Stock Information
- Founded
- AKYA 2015
- CHRS 2010
- Country
- AKYA United States
- CHRS United States
- Employees
- AKYA N/A
- CHRS N/A
- Industry
- AKYA Medical Specialities
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKYA Industrials
- CHRS Health Care
- Exchange
- AKYA Nasdaq
- CHRS Nasdaq
- Market Cap
- AKYA 152.2M
- CHRS 134.4M
- IPO Year
- AKYA 2021
- CHRS 2014
- Fundamental
- Price
- AKYA $2.05
- CHRS $1.07
- Analyst Decision
- AKYA Buy
- CHRS Strong Buy
- Analyst Count
- AKYA 7
- CHRS 4
- Target Price
- AKYA $4.40
- CHRS $5.38
- AVG Volume (30 Days)
- AKYA 375.0K
- CHRS 2.0M
- Earning Date
- AKYA 03-07-2025
- CHRS 03-12-2025
- Dividend Yield
- AKYA N/A
- CHRS N/A
- EPS Growth
- AKYA N/A
- CHRS N/A
- EPS
- AKYA N/A
- CHRS N/A
- Revenue
- AKYA $86,815,000.00
- CHRS $304,340,000.00
- Revenue This Year
- AKYA N/A
- CHRS $2.07
- Revenue Next Year
- AKYA $11.90
- CHRS N/A
- P/E Ratio
- AKYA N/A
- CHRS N/A
- Revenue Growth
- AKYA N/A
- CHRS 44.19
- 52 Week Low
- AKYA $1.88
- CHRS $0.66
- 52 Week High
- AKYA $6.31
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- AKYA 32.17
- CHRS 39.03
- Support Level
- AKYA $2.21
- CHRS $1.06
- Resistance Level
- AKYA $2.37
- CHRS $1.16
- Average True Range (ATR)
- AKYA 0.15
- CHRS 0.08
- MACD
- AKYA -0.06
- CHRS 0.00
- Stochastic Oscillator
- AKYA 8.79
- CHRS 5.56
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.